although β-glucan exhibits various biological activities, the anticancer mechanisms of a low-molecular-weight β -glucan isolated from Aureobasidium pullulans (lMW-aP-FBG) in colorectal cancer remain unclear.Therefore, this study investigated the anticancer potential of lMW-aP-FBG in human colon cancer cells.Treatment of SW480 cells with lMW-aP-FBG resulted in a significant reduction in cell viability in a concentration-and time-dependent manner, with half-maximal inhibitory concentrations (ic 50 ) of 557.2, 497.4 and 300.6 µg/ml at 24, 48 and 72 h, respectively.apoptotic cell death was evidenced by increased caspase-3/7 enzymatic activity and proteolytic cleavage of caspase-3, -7, -8, -9 and poly (adP-ribose) polymerase.notably, pharmacological inhibition of caspases using the pan-caspase inhibitor Z-Vad-FMK only partially restored cell viability, suggesting the involvement of caspase-independent cell death mechanisms.Mitochondrial dysfunction was further indicated by dissipation of mitochondrial membrane potential, cytosolic accumulation of cytochrome c, and downregulation of the anti-apoptotic protein Bcl-2, collectively supporting activation of the intrinsic apoptotic pathway. in parallel, the expression of autophagy-related proteins was markedly increased, implying concomitant induction of autophagic processes.Mechanistically, lMW-aP-FBG suppressed the Pi3K/aKT/mTor signaling axis, a central regulator of cell survival and autophagy.Collectively, these findings demonstrate that lMW-aP-FBG exerts anticancer effects in SW480 colon cancer cells through coordinated activation of apoptotic and autophagy-associated pathways, highlighting its potential as a bioactive anticancer agent and warranting further in vivo validation.